Trials & R&D · first seen 22h ago, updated 22h ago

Merck sees pivotal victory for $3B eye disease prospect

1 outlet Merck & Co. (MSD)

Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion takeover.

Summary from Fierce Biotech - Biotech.

Coverage 1 article · 1 outlet

Fierce Biotech - Biotech 22h ago
Merck sees pivotal victory for $3B eye disease prospect